Microbiology & Virology

Equity, diversity and inclusion for all

Jemma Shead, a Senior Biomedical Scientist at Synnovis and IBMS EDI Working Group member, on how and why you should get involved with EDI.

Examining the medical mystery of child hepatitis outbreak

A study has shed light on an unexpected wave of severe acute hepatitis cases in 2022, amid the backdrop of the ongoing global COVID-19 pandemic.

Faecal microbiota transplant for C. diff

In the first comprehensive US evidence-based guideline on the use of faecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends faecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.

Tackling priority pathogen with phages

A new study describes the use of phage therapy to eradicate multidrug-resistant Pseudomonas aeruginosa infections in vivo with important new implications for antibiotic resistance.

My lab: Clinical microbiology service

Senior Biomedical Scientist James Griffiths gives a guided tour of his lab at the Royal Cornwall Hospital in Truro.

Tech news: March 2024

This month's top tech news stories

Iodine antiseptic and surgical-site infections

A large multicentre clinical trial found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic.

Crimean-Congo haemorrhagic fever

Dr Arantza Portillo discusses the changing epidemiology of this tick-borne viral disease in Spain and looks at the future situation for the UK.

Skin bacterium that inhibits antibiotic-resistant bacteria growth

A research group looking at antibiotic-resistant bacteria has reported promising results with a study on bacteriocins – substances that bacteria produce to inhibit the growth of competitors.

“Monkeypox virus evolving due to human transmission”

A new analysis shows the monkeypox virus (MPXV) is rapidly diverging into several lineages characterised by mutations resulting from continued interaction with the human immune system, suggesting that the virus has been circulating in humans since 2016.

Top